1Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
© 2025 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
FUNDING
None.
ACKNOWLEDGMENTS
None.
AUTHOR CONTRIBUTIONS
Conceptualization: JC, SYK, YHC. Data curation: all authors. Writing - original draft: JC, SYK. Writing -review & editing: YHC. All authors read and agreed to the published version of the manuscript.
Modality | IABP | Impella | Direct LV venting | PAS | PAD | Transseptal LA canulation |
---|---|---|---|---|---|---|
Primary mode of action | Afterload reduction | Active pumping of blood from LV to aorta | Active draining of blood from LV | Preload reduction | Preload reduction | Preload reduction |
LV unloading | + | ++++ | ++++ | ++ | + | ++ |
Lung protection | + | ++++ | ++++ | ++ | + | +++ |
The risk of Harlequin syndrome | Possible | Possible | Less likely | Less likely | Less likely | Less likely |
Increase in antegrade flow | Yes | Yes | No (could decrease) | No (could decrease) | No (could decrease) | No (could decrease) |
Dependency on LV function | Yes | No | No | No | No | No |
Efficacy for LVEDP reduction | + | +++++ | +++++ | +++ to ++++ | +++ | a)++++ |
LV energetics | ||||||
PVA ↓ | + | + | + | + | + | + |
PE ↓ | (+) | (+) | (+) | (+) | (–) | (+) |
SW ↓ | (–) | (–) | (–) | (+) | (+) | (+) |
LV: left ventricular; IABP: intra-aortic balloon pump; PAS: percutaneous atrial septostomy; PAD: pulmonary artery drainage; LA: left atrial; LVEDP: left ventricular end-diastolic pressure; PVA: pressure volume area; PE: potential energy; SW: stroke work; ↓, Decreasing.
a)No available data from human or animal experimental model (simulation data was not adopted).
Modality | IABP | Impella | Direct LV venting | PAS | PAD | Transseptal LA canulation |
---|---|---|---|---|---|---|
Primary mode of action | Afterload reduction | Active pumping of blood from LV to aorta | Active draining of blood from LV | Preload reduction | Preload reduction | Preload reduction |
LV unloading | + | ++++ | ++++ | ++ | + | ++ |
Lung protection | + | ++++ | ++++ | ++ | + | +++ |
The risk of Harlequin syndrome | Possible | Possible | Less likely | Less likely | Less likely | Less likely |
Increase in antegrade flow | Yes | Yes | No (could decrease) | No (could decrease) | No (could decrease) | No (could decrease) |
Dependency on LV function | Yes | No | No | No | No | No |
Efficacy for LVEDP reduction | + | +++++ | +++++ | +++ to ++++ | +++ | |
LV energetics | ||||||
PVA ↓ | + | + | + | + | + | + |
PE ↓ | (+) | (+) | (+) | (+) | (–) | (+) |
SW ↓ | (–) | (–) | (–) | (+) | (+) | (+) |
LV: left ventricular; IABP: intra-aortic balloon pump; PAS: percutaneous atrial septostomy; PAD: pulmonary artery drainage; LA: left atrial; LVEDP: left ventricular end-diastolic pressure; PVA: pressure volume area; PE: potential energy; SW: stroke work; ↓, Decreasing. No available data from human or animal experimental model (simulation data was not adopted).